)

Isofol Medical (ISOFOL) investor relations material
Isofol Medical Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Transitioned from planning to execution phase with a successful, fully guaranteed and oversubscribed rights issue, raising SEK 91 million gross and strengthening the financial position for continued clinical development.
Positive progress in the phase Ib/II clinical study for arfolitixorin, with the first cohort completed and the next dose level initiated.
Constructive pre-IND meeting with the FDA validated the clinical development plan for arfolitixorin in the U.S.
Japanese partner Solasia Pharma K.K. to finance and conduct phase II/III studies in Japan, expanding the clinical program's reach.
Participation in major scientific and business conventions, and establishment of a new advisory board.
Financial highlights
No revenue reported; net loss for Q2 was SEK -14.7 million, compared to SEK -11 million in Q2 last year; H1 2025 net loss was SEK -28.3 million, up from SEK -19.5 million year-over-year.
Cash and cash equivalents at June 30, 2025, were SEK 65.7 million, down from SEK 119.2 million a year earlier, prior to the rights issue completed in July.
Cash flow for the quarter was SEK -17 million, compared to SEK -9 million the previous year.
Operating costs increased due to higher personnel and external costs related to clinical studies.
No loans or material investments; R&D costs expensed as incurred.
Outlook and guidance
Strengthened cash position post-rights issue provides funding for at least the next 12 months.
Ongoing phase Ib/II study to continue with escalating doses and potential expansion to Japan in 2026.
Clinical trial is progressing as planned, with updates to be provided as cohorts advance.
Further updates on clinical progress and business development expected throughout the year.
Next Isofol Medical earnings date

Next Isofol Medical earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage